Search for: "Amgen Inc" Results 1 - 20 of 696
Sort by Relevance | Sort by Date
RSS Subscribe: 20 results | 100 results
25 Jan 2024, 6:32 am by Daniel J. Gilman
  The FTC also touted its settlement of the Amgen/Horizon matter (here and here) although, as I explained in December, the core of the consent order—reached on the eve of trial—had been proposed by Amgen all along. [read post]
18 Jan 2024, 5:14 pm by bklemm@foley.com
Share on LinkedInShare on TwitterShare by EmailShare Back to top The USPTO has issued “Guidelines for Assessing Enablement in Utility Applications and Patents in View of the Supreme Court Decision in Amgen Inc. et al. v. [read post]
11 Jan 2024, 12:59 pm by Dennis Crouch
Genentech, Inc., 81 F.4th 1362 (Fed. [read post]
11 Dec 2023, 5:05 am by Rob Robinson
Companies across the pharmaceutical landscape are adapting to this new environment, including Amgen Inc., whose $43 billion takeover of Seagen Inc. faces a rigorous FTC review. [read post]
4 Dec 2023, 10:00 pm by Sherica Celine
Watch now » Related Content Amgen Patent Ruling's Impact Extends Beyond Life Sciences Gain insight from Law360 expert analysis on the impacts of Amgen Inc. v. [read post]
29 Nov 2023, 8:41 am by Dennis Crouch
The Federal Circuit rejected this argument based on dicta in Thryv, Inc. v. [read post]
4 Oct 2023, 5:27 pm by Scott McKeown
As a reminder the SCOTUS in Amgen warned that “the more one claims, the more one must enable” Amgen Inc. v. [read post]
3 Oct 2023, 4:15 am by Kirk Hartung
The Supreme Court decided Amgen Inc. v. [read post]